<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269215</url>
  </required_header>
  <id_info>
    <org_study_id>599.2</org_study_id>
    <nct_id>NCT02269215</nct_id>
  </id_info>
  <brief_title>Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers</brief_title>
  <official_title>A Single Blind, Placebo-controlled, Parallel-group, Single Increasing Dose Tolerance Study in Healthy Young Male Volunteers After Intravenous Administration of BIII 890 CL as Loading Dose (Dosage: 12.5, 25, 50 mg/h, Infusion Time 1 hr; 50 mg/h, Infusion Time 2 Hrs) Followed by Maintenance Dose (Dosage: 6.25, 12.5, 25 mg/h, Infusion Time 5 Hrs; 30 mg/h, Infusion Time 4 Hrs) and in Healthy Elderly Male and Female Volunteers After Intravenous Administration of BIII 890 CL as Loading Dose (Dosage: 50 mg/h, Infusion Time 1 hr) Followed by Maintenance Dose (Dosage: 25 mg/h, Infusion Time 5 Hrs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Safety, tolerability and pharmacokinetics of BIII 890
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <primary_completion_date type="Actual">September 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with clinically relevant changes in vital signs</measure>
    <time_frame>Pre-dose, up to 8 days after drug administration</time_frame>
    <description>blood pressure, pulse rate, respiratory rate, body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically relevant changes in 12-lead ECG</measure>
    <time_frame>Pre-dose, up to 8 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically relevant changes in laboratory parameters</measure>
    <time_frame>Pre-dose, up to 8 days after drug administration</time_frame>
    <description>including coagulation parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Up to 8 days after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>up to 32 hours after start of drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum concentration of the analyte in plasma over a uniform dosing interval λz (tmax)</measure>
    <time_frame>up to 32 hours after start of drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life of the analyte in plasma (t1/2)</measure>
    <time_frame>up to 32 hours after start of drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma (AUC)</measure>
    <time_frame>up to 32 hours after start of drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>up to 32 hours after start of drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma clearance (CL)</measure>
    <time_frame>up to 32 hours after start of drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (V)</measure>
    <time_frame>up to 32 hours after start of drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of parent drug excreted into urine (Ae)</measure>
    <time_frame>up to 32 hours after start of drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIII 890 CL single rising dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIII 890 CL</intervention_name>
    <arm_group_label>BIII 890 CL single rising dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants in the study should be healthy males, range from 21 to 50 years of age
             and be within +- 20% of their normal weight (Broca-Index) and healthy elderly males
             and females, &gt; 60 years of age and be within +-25 % of their normal weight
             (Broca-Index)

          -  In accordance with good clinical practice (GCP) and the local legislation all
             volunteers will have given their written informed consent prior to admission to the
             study

        Exclusion Criteria:

          -  Volunteers were excluded from the study if the results of the medical examination,
             laboratory tests or ECG recordings are judged by the investigator to differ
             significantly from normal clinical values

          -  Volunteers with known gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunological or hormonal disorders

          -  Volunteers with diseases of the central nervous system (such as epilepsy), central
             nervous system (CNS) trauma in their medical history or with psychiatric disorders or
             neurological disorders

          -  Volunteers with known history of relevant orthostatic hypotension, fainting spells or
             blackouts

          -  Volunteers with chronic or relevant acute infections

          -  Volunteers with history of allergy/hypersensitivity (including drug allergy) which was
             deemed relevant to the trial as, judged by the investigator

          -  Volunteers who had taken a drug with a long half-life (≥ 24 hours) within at least one
             month or less than ten half-lives of the respective drug before enrolment in the study

          -  Volunteers who received any other drugs which could influence the results of the trial
             during the week prior to the start of the study

          -  Volunteers who participated in another study with an investigational drug within the
             last two months preceding this study

          -  Volunteers who smoke (&gt; 10 cigarettes or 3 cigars or 3 pipes/day)

          -  Volunteers who were not able to refrain from smoking on study days

          -  Volunteers who drunk more than 60 g of alcohol per day

          -  Volunteers who were dependent on drugs

          -  Volunteers who participated in excessive physical activities (e.g. competitive sports)
             during the last week before the study

          -  Volunteers who donated blood within the last 4 weeks (≥ 100 mL)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>October 20, 2014</last_update_submitted>
  <last_update_submitted_qc>October 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

